| 1 |
35196359 | Increased dosage and treatment time of Epigallocatechin-3-gallate (EGCG) negatively affects skeletal parameters in normal mice and Down syndrome mouse models. | 2022 |
2 |
| 2 |
32092951 | Molecular Rescue of Dyrk1A Overexpression Alterations in Mice with Fontup® Dietary Supplement: Role of Green Tea Catechins. | 2020 Feb 19 |
2 |
| 3 |
32591597 | Evaluation of the therapeutic potential of Epigallocatechin-3-gallate (EGCG) via oral gavage in young adult Down syndrome mice. | 2020 Jun 26 |
2 |
| 4 |
30850713 | Prenatal treatment with EGCG enriched green tea extract rescues GAD67 related developmental and cognitive defects in Down syndrome mouse models. | 2019 Mar 8 |
3 |
| 5 |
31803016 | DYRK1A Overexpression Alters Cognition and Neural-Related Proteomic Pathways in the Hippocampus That Are Rescued by Green Tea Extract and/or Environmental Enrichment. | 2019 |
2 |
| 6 |
28203607 | Epigallocatechin gallate: A useful therapy for cognitive disability in Down syndrome? | 2017 |
6 |
| 7 |
28377597 | Dyrk1A overexpression leads to increase of 3R-tau expression and cognitive deficits in Ts65Dn Down syndrome mice. | 2017 Apr 4 |
3 |
| 8 |
28478033 | Epigallocatechin-3-gallate (EGCG) consumption in the Ts65Dn model of Down syndrome fails to improve behavioral deficits and is detrimental to skeletal phenotypes. | 2017 Aug 1 |
2 |
| 9 |
28944229 | Targeting trisomic treatments: optimizing Dyrk1a inhibition to improve Down syndrome deficits. | 2017 Sep |
2 |
| 10 |
26748562 | Differential effects of Epigallocatechin-3-gallate containing supplements on correcting skeletal defects in a Down syndrome mouse model. | 2016 Apr |
2 |
| 11 |
27457036 | Short- and long-term effects of neonatal pharmacotherapy with epigallocatechin-3-gallate on hippocampal development in the Ts65Dn mouse model of Down syndrome. | 2016 Oct 1 |
2 |
| 12 |
28172997 | Influence of prenatal EGCG treatment and Dyrk1a dosage reduction on craniofacial features associated with Down syndrome. | 2016 Nov 15 |
2 |
| 13 |
26206885 | Rescue of the abnormal skeletal phenotype in Ts65Dn Down syndrome mice using genetic and therapeutic modulation of trisomic Dyrk1a. | 2015 Oct 15 |
1 |
| 14 |
26539088 | Pharmacological correction of excitation/inhibition imbalance in Down syndrome mouse models. | 2015 |
2 |
| 15 |
24039182 | Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans. | 2014 Feb |
5 |
| 16 |
24453307 | Prefrontal deficits in a murine model overexpressing the down syndrome candidate gene dyrk1a. | 2014 Jan 22 |
2 |
| 17 |
23969234 | Environmental enrichment rescues DYRK1A activity and hippocampal adult neurogenesis in TgDyrk1A. | 2013 Dec |
2 |
| 18 |
21135538 | Overexpression of Dyrk1A causes the defects in synaptic vesicle endocytosis. | 2010 |
1 |
| 19 |
19242551 | Green tea polyphenols rescue of brain defects induced by overexpression of DYRK1A. | 2009 |
2 |
| 20 |
17002300 | Kinetic properties of a MNB/DYRK1A mutant suitable for the elucidation of biochemical pathways. | 2006 Oct 3 |
4 |